通过高强度功能训练增强轻度认知障碍的老年人认知能力:单盲随机对照试验
Yulieth Rivas-Campo1, Agustín Aibar-Almazán2, Carlos Rodríguez-López3
1Faculty of Human and Social Sciences, University of San Buenaventura-Cali, Santiago de Cali 760016, Colombia.
Journal of clinical medicine
|June 28, 2023
概括
高强度间歇功能训练 (HIFT) 在轻度认知障碍的老年人中显著改善了认知功能,包括注意力和语言流性. 这项运动计划提供了一种有前途的非药物治疗方法,以提高老年人的认知健康.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 运动生理学 运动生理学
背景情况:
- 认知能力下降是老年人群的一个重大问题.
- 寻求非药物干预来缓解与年龄相关的认知障碍.
- 轻度认知障碍 (MCI) 影响了大量的老年人.
研究的目的:
- 评估高强度间歇功能训练 (HIFT) 计划对老年哥伦比亚人患有MCI的认知功能的影响.
- 将HIFT干预的认知结果与接受一般身体活动建议的对照组进行比较.
主要方法:
- 一项受控的临床试验涉及132名65岁以上的MCI参与者.
- 随机分配给一个为期3个月的HIFT计划 (干预组) 或一般体力活动 (对照组).
- 认知评估包括MoCA,TMTA,TMTB,VFAT,DSST,以及d2测试.
主要成果:
- 与对照组相比,HIFT组在认知障碍 (MoCA),注意力 (TMTA),口语流性和注意力方面的显著改善 (p < 0.001).
- 执行功能 (TMTB) 在HIFT组也显示出改善 (p = 0.037).
- 在选择性注意力或处理速度方面没有观察到显著差异.
结论:
- 在被诊断患有轻度认知障碍的老年人中,HIFT计划对认知功能有积极的影响.
- 这些发现支持将HIFT纳入老年人群的治疗策略.
- 高强度和功能性质的HIFT似乎特别有利于老年人的认知健康.
相关概念视频
01:30Cognitive Development During Adulthood
160
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
160
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
163
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
163
01:22Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222